Heron Therapeutics Inc. (NASDAQ:HRTX) – Equities research analysts at Leerink Swann issued their Q1 2017 earnings per share (EPS) estimates for shares of Heron Therapeutics in a research report issued on Thursday. Leerink Swann analyst J. Gerberry forecasts that the brokerage will post earnings of ($0.77) per share for the quarter. Leerink Swann currently has a “Buy” rating and a $33.00 target price on the stock. Leerink Swann also issued estimates for Heron Therapeutics’ Q2 2017 earnings at ($0.79) EPS, Q3 2017 earnings at ($0.60) EPS and Q4 2017 earnings at ($0.15) EPS.

Several other equities research analysts have also weighed in on the company. Jefferies Group reissued a “buy” rating and issued a $46.00 price objective on shares of Heron Therapeutics in a report on Wednesday, July 27th. Brean Capital reissued a “buy” rating and issued a $55.00 price objective on shares of Heron Therapeutics in a report on Saturday, August 13th. Cantor Fitzgerald reissued a “buy” rating and issued a $41.00 price objective on shares of Heron Therapeutics in a report on Wednesday, August 3rd. Zacks Investment Research raised Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 31st. Finally, Lake Street Capital reissued a “buy” rating and issued a $45.00 price objective on shares of Heron Therapeutics in a report on Tuesday, September 6th. One investment analyst has rated the stock with a sell rating and eight have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $42.14.

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Heron Therapeutics (NASDAQ:HRTX) opened at 16.83 on Friday. The stock has a 50 day moving average of $18.62 and a 200-day moving average of $18.90. Heron Therapeutics has a 12-month low of $15.13 and a 12-month high of $31.32.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Monday, August 8th. The biotechnology company reported ($1.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.96) by $0.21.

In other Heron Therapeutics news, insider Robert Rosen sold 100,000 shares of Heron Therapeutics stock in a transaction dated Wednesday, August 10th. The stock was sold at an average price of $23.30, for a total transaction of $2,330,000.00. Following the completion of the transaction, the insider now owns 102,640 shares of the company’s stock, valued at approximately $2,391,512. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 20.31% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Cormorant Asset Management LLC raised its position in Heron Therapeutics by 3.8% in the first quarter. Cormorant Asset Management LLC now owns 1,750,000 shares of the biotechnology company’s stock worth $33,233,000 after buying an additional 64,281 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Heron Therapeutics by 6.0% in the first quarter. JPMorgan Chase & Co. now owns 348,685 shares of the biotechnology company’s stock valued at $6,622,000 after buying an additional 19,737 shares during the last quarter. VHCP Management II LLC acquired a new position in shares of Heron Therapeutics during the first quarter valued at approximately $7,708,000. California State Teachers Retirement System raised its position in shares of Heron Therapeutics by 7.6% in the second quarter. California State Teachers Retirement System now owns 66,632 shares of the biotechnology company’s stock valued at $1,203,000 after buying an additional 4,732 shares during the last quarter. Finally, Franklin Resources Inc. raised its position in shares of Heron Therapeutics by 28.2% in the first quarter. Franklin Resources Inc. now owns 7,523,278 shares of the biotechnology company’s stock valued at $142,869,000 after buying an additional 1,653,008 shares during the last quarter.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

5 Day Chart for NASDAQ:HRTX

Receive News & Stock Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related stocks with our FREE daily email newsletter.